Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma

Genes Chromosomes and Cancer

Volumn 41, Issue 4, 2004, Pages 297-308

  Gebauer, Sigrun ^a   Yu, Alice L ^a   Omura Minamisawa, Motoko ^b   Batova, Ayse ^a   Diccianni, Mitchell B ^a  

^a UCSD MEDICAL CENTER   (United States)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CDKN1B GENE; CDKN2A GENE; CELL STRAIN HL 60; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; ID2 GENE; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA-BINDING PROTEINS; GENES, P16; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 2; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; REPRESSOR PROTEINS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 8444227483     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20096     Document Type: Article

References (53)

1. Beltinger CP, White PS, Sulman EP, Maris JM, Brodeur GM. 1995. No CDKN2 mutations in neuroblastoma. Cancer Res 55:2053-2055.
2. Benezra R, Davis RL, Lassar A, Tapscott S, Thayer M, Lockshon D, Weintraub H. 1990. Id: a negative regulator of helix-loop-helix DNA binding proteins. Control of terminal myogenic differentiation. Ann NY Acad Sci 599:1-11.
3. Bergmann E, Wanzel M, Weber A, Shin I, Christiansen H, Eilers M. 2001. Expression of P27(KIP1) is prognostic and independent of MYCN amplification in human neuroblastoma. Int J Cancer 95:176-183.
4. Borriello A, Pietra VD, Criscuolo M, Oliva A, Tonini GP, Iolascon A, Zappia V, Ragione FD. 2000. p27(Kip1) accumulation is associated with retinoic-induced neuroblastoma differentiation: evidence of a decreased proteasome-dependent degradation. Oncogene 19:51-60.
5. Brodeur GM. 2002. Significance of intratumoral genetic heterogeneity in neuroblastomas. Med Pediatr Oncol 38:112-113.
6. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. 1984. Amplification of MYCN in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121-1124.
7. Diccianni MB, Chau LS, Batova A, Vu TQ, Yu AL. 1996. The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance. Cancer Letters 104:183-192.
8. Diccianni MB, Omura-Minamisawa M, Batova A, Le T, Bridgeman L, Yu AL. 1999. Frequent deregulation of p16 and the p16/G1 cell cycle-regulatory pathway in neuroblastoma. Int J Cancer 80:145-154.
9. Dong Y, Walsh MD, McGuckin MA, Gabrielli BG, Cummings MC, Wright RG, Hurst T, Khoo SK, Parsons PG. 1997. Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 74:57-63.
10. Easton J, Wei T, Lahti JM, Kidd VJ. 1998. Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma. Cancer Res 58:2624-2632.
11. Ellenberger T, Fass D, Arnaud M, Harrison SC. 1994. Crystal structure of transcription factor E47: E-box recognition by a basic region helix-loop-helix dimer. Genes Dev 8:970-980.
12. Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Cena V, Gallego C, Comella JX. 2000. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem 75:991-1003.
13. Gebauer S, Diccianni M, Gebauer G, Yu A. 2002. P16 expression is not correlated with expression of Id2 or the loss of p27kip1 at protein level in advanced stage neuroblastoma (abstract). Proc Am Assoc Cancer Res 43:624.
14. Hacker C, Kirsch RD, Ju XS, Hieronymus T, Gust TC, Kuhl C, Jorgas T, Kurz SM, Rose-John S, Yokota Y, Zenke M. 2003. Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol 4:380-386.
15. Halvorsen OJ, Hostmark J, Haukaas S, Hoisaeter PA, Akslen LA. 2000. Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer 88:416-424.
16. Iavarone A, Garg P, Lasorella A, Hsu J, Israel MA. 1994. The helix-loop-helix protein Id-2 enhances cell proliferation and binds to the retinoblastoma protein. Genes Dev 8:1270-1284.
17. Ishiguro A, Spirin KS, Shiohara M, Tobler A, Gombart AF, Israel MA, Norton JD, Koeffler HP. 1996. Id2 expression increases with differentiation of human myeloid cells. Blood 87:5225-5231.
18. Jan YN, Jan LY. 1993. HLH proteins, fly neurogenesis, and vertebrate myogenesis. Cell 75:827-830.
19. Jarrard DF, Modder J, Fadden P, Fu V, Sebree L, Heisey D, Schwarze SR, Friedl A. 2002. Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostate cancer. Cancer Lett 185:191-199.
20. Jogi A, Ora I, Nilsson H, Lindeheim A, Makino Y, Poellinger L, Axelson H, Pahlman S. 2002. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci USA 99:7021-7026.
21. Kawamata N, Seriu T, Koeffler HP, Bartram CR. 1996. Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas. Cancer 77:570-575.
22. Knoepfler PS, Cheng PF, Eisenman RN. 2002. MYCN is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 16:2699-2712.
23. Kranenburg O, Scharnhorst V, Van der Eb AJ, Zantema A. 1995. Inhibition of cyclin-dependent kinase activity triggers neuronal differentiation of mouse neuroblastoma cells. J Cell Biol 131:227-234.
24. Kurabayashi M, Jeyaseelan R, Kedes L. 1993. Two distinct cDNA sequences encoding the human helix-loop-helix protein Id2. Gene 133:305-306.
25. Lasorella A, Iavarone A, Israel MA. 1996. Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins. Mol Cell Biol 16:2570-2578.
26. Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A. 2000. Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 407:592-598.
27. Lasorella A, Boldrini R, Dominici C, Donfrancesco A, Yokota Y, Inserra A, Iavarone A. 2002. Id2 is critical for cellular proliferation and is the oncogenic effector of MYCN in human neuroblastoma. Cancer Res 62:301-306.
28. Lassar AB, Davis RL, Wright WE, Kadesch T, Murre C, Voronova A, Baltimore D, Weintraub H. 1991. Functional activity of myogenic HLH proteins requires hetero- oligomerization with E12/E47-like proteins in vivo. Cell 66:305-315.
29. Lee CT, Capodieci P, Osman I, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C. 1999. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res 5:977-983.
30. Matsuo T, Thiele CJ. 1998. p27Kip1: a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line. Oncogene 16:3337-3343.
31. Matsuo T, Seth P, Thiele CJ. 2001. Increased expression of p27Kip1 arrests neuroblastoma cell growth. Med Pediatr Oncol 36:97-99.
32. Murre C, McCaw PS, Vaessin H, Caudy M, Jan LY, Jan YN, Cabrera CV, Buskin JN, Hauschka SD, Lassar AB, Weintraub H, Baltimore D. 1989. Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence. Cell 58:537-544.
33. Nho RS, Sheaff RJ. 2003. p27kip1 contributions to cancer. Prog Cell Cycle Res 5:249-259.
34. Olson EN, Klein WH. 1994. bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out. Genes Dev 8:1-8.
35. Omura-Minamisawa M, Diccianni MB, Chang RC, Batova A, Bridgeman LJ, Schiff J, Cohn SL, London WB, Yu AL. 2001. p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease. Clin Cancer Res 7:3481-3490.
36. Philipp-Staheli J, Payne SR, Kemp CJ. 2001. p27(Kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 264:148-168.
37. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. 1994. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8:9-22.
38. Raetz EA, Kim MK, Moos P, Carlson M, Bruggers C, Hooper DK, Foot L, Liu T, Seeger R, Carroll WL. 2003. Identification of genes that are regulated transcriptionally by Myc in childhood tumors. Cancer 98:841-853.
39. Rocco JW, Sidransky D. 2001. p16(MTS-1)/CDKN2/INK4a) in cancer progression. Exp. Cell Res 264:42-55.
40. Sato Y, Kobayashi Y, Sasaki H, Toyama T, Kondo S, Kiriyama M, Fujii Y. 2003. Expression of Id2 mRNA in neuroblastoma and normal ganglion. Eur J Surg Oncol 29:284-287.
41. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. 1985. Association of multiple copies of the MYCN oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116.
42. Sgambato A, Cittadini A, Faraglia B, Weinstein IB. 2000. Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. J Cell Physiol 183:18-27.
43. Shen L, Tsuchida R, Miyauchi J, Saeki M, Honna T, Tsunematsu Y, Kato J, Mizutani S. 2000. Differentiation-associated expression and intracellular localization of cyclin-dependent kinase inhibitor p27KIP1 and c-Jun co-activator JAB1 in neuroblastoma. Int J Oncol 17:749-754.
44. Sherr CJ. 2004. Principles of tumor suppression. Cell 116:235-246.
45. Sherr CJ, Roberts JM. 1999. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512.
46. Shigemasa K, Hu C, West CM, Clarke J, Parham GP, Parmley TH, Korourian S, Baker VV, O'Brien TJ. 1997. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma. J Soc Gynecol Investig 4:95-102.
47. Sun XH, Copeland NG, Jenkins NA, Baltimore D. 1991. Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins. Mol Cell Biol 11:5603-5611.
48. Tanaka T, Slamon DJ, Shimoda H, Waki C, Kawaguchi Y, Tanaka Y, Ida N. 1988. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis. Cancer Res 48:1030-1034.
49. Tweddle DA, Pearson AD, Haber M, Norris MD, Xue C, Flemming C, Lunec J. 2003. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett 197:93-98.
50. Vandesompele J, Edsjo A, De Preter K, Axelson H, Speleman F, Pahlman S. 2003. Id2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value. Oncogene 22:456-460.
51. Viglietto G, Fusco A. 2002. Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization? Cell Cycle 1:394-400.
52. Wang Q, Hii G, Sbusterman S, Mosse Y, Winter CL, Guo C, Zhao H, Rappaport E, Hogarty MD, Maris JM. 2003. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas. Cancer Res 63:1631-1635.
53. Weintraub H. 1993. The MyoD family and myogenesis: redundancy, networks, and thresholds. Cell 75:1241-1244.